28.05.2023, 2488 Zeichen

Marinomed: Marinomed Biotech AG reported new record revenues in the first quarter of 2023 (+38% to € 3.3 million after € 2.4 million Q1 2022) and thus the strongest first quarter in the Company's history. This dynamic development was driven especially by the successful establishment of Carragelose as a broadly effective virus blocker in a particularly strong flu and cold season. Because of higher R&D expenses, the operating result remained at a similar level of € -1.4 million compared to the same period last year (Q1 2022: € -1.2 million). The cash position as of March 31, 2023 remained solid at € 7.0 million. Andreas Grassauer, CEO of Marinomed, says: "In the first quarter of 2023, we were able to demonstrate that Carragelose is a sustainably growing business in the post-pandemic environment. With new clinical data published in the first quarter on the efficacy of Carragelose against hay fever, we were also able to create the basis for a future all-season product portfolio. Accordingly, we are currently preparing the marketing of Carragelose for the next allergy season. Preparations for our market entry in the USA together with Procter & Gamble are also in full swing, as well as the partnering processes for our most valuable product candidates Tacrosolv and Budesolv."

Zumtobel: Lightning group Zumtobel has joined the Science Based Targets initiative (SBTi). Together with over 4,000 participating companies worldwide, this initiative aims to contribute to limiting global warming to 1.5°C on the basis of science-based, individual targets. The Austrian lighting group is hereby committed to reducing CO2 emissions along the entire value chain in line with science-based net-zero targets. "Joining the Science Based Targets initiative is a big step. We are taking responsibility for emissions that go beyond our own production: Reducing upstream and downstream emissions is now also part of our sustainability goals and will not only accompany us over the next few years, but guide us. Transformation and innovation will be essential building blocks on the way to net-zero", CEO Alfred Felder says.

CA Immo: In the last few weeks, CA Immo has concluded and extended seven leases for around 40 % (approx. 1,900 m²) of the space in the Nymphenburg medical centre in the Ambigon building in Munich. All rental agreements were concluded on a long-term basis with a term of 10 years.

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/05/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #789: ATX verliert trotz sehr starker VIG, der Erste Bank George fehlt mir heute sehr, dazu ein S Immo Zufall

Bildnachweis

Aktien auf dem Radar:voestalpine, Pierer Mobility, Warimpex, Addiko Bank, CA Immo, Immofinanz, Verbund, ATX, ATX Prime, ATX TR, Bawag, Andritz, Österreichische Post, AT&S, Cleen Energy, Frauenthal, Kostad, Oberbank AG Stamm, Kapsch TrafficCom, DO&CO, Agrana, Amag, Erste Group, EVN, Flughafen Wien, OMV, Palfinger, RHI Magnesita, Semperit, S Immo, Telekom Austria.

---